🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

RecruitingPhase 3Ages 18 Years - 90 YearsAllFu Jen Catholic University Hospital
NCT07736911 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week). * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose. * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication. * Age between 18 and 70 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Provision of written informed consent. * Outpatient status. * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD. Exclusion Criteria: * • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus). * Any other condition deemed inappropriate by the treating physician. * Body mass index (BMI) \> 40 kg/m². * Liver cirrhosis. * Parkinson's disease. * Dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.
💊

What it tests

  • GLP-1 Stop for 1 week
  • GLP-1 non stop
📍

Where

1 site
FJUH
New Taipei City, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy